New weight loss drugs: GLP-1 agonist use and side effects in the United States (Research Report No
Serious but rarer risks include pancreatitis, gallbladder disease, and increased heart rate
Similar concerns have been seen with lipid outcomes with an increase in total cholesterol after cessation of semaglutide to near pretreatment levels and loss of around two-thirds of the benefit in triglycerides, while positive changes in LDL-C and HDL-C were more modest but appeared more durable (Table 2) [73]
Allergic reaction: This may involve swelling of the face, lips, tongue, or throat, along with difficulty breathing or swallowing and a fast heartbeat
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management
Patients may or may not obtain follow-up and/or referrals to RDs